Seagen Inc.

SGEN

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase3 readout (tucatinib): Jun 2023.

BiotechnologyCEO: David R. EpsteinIPO: 2001Website ↗

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Recent News & Research

PubMed

Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin's Lymphoma: A Multi-Center Retrospective Study on Survival and Safety.

# Investment Summary: Brentuximab Vedotin in R/R cHL This retrospective study evaluates brentuximab vedotin (Adcetris) monotherapy outcomes in refractory/relapsed classical Hodgkin's lymphoma, a key indication for Seagen's approved agent. The data on survival and safety profiles in a multi-center cohort provides real-world evidence on Adcetris performance in R/R cHL, informing durability and market positioning relative to competing checkpoint inhibitors and combination regimens. **Why it matters:** As a mature product competing against newer PD-1 inhibitors and combination approaches, real-world safety and efficacy data help validate Adcetris' continued clinical relevance and support pricing/reimbursement arguments, though monotherapy use has shifted toward combination strategies in recent practice patterns.

May 1, 2026

PubMed

Bilateral adrenal infarction during brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisolone therapy for ALK-negative anaplastic large cell lymphoma: A case report.

# Investment Summary: SGEN Adverse Event Alert A case report documents bilateral adrenal infarction in an ALCL patient receiving brentuximab vedotin (BV, Adcetris) combination chemotherapy, a rare but serious thromboembolic complication not previously characterized in clinical trial populations. While single case reports have limited statistical weight, this adverse event could trigger additional safety monitoring requirements, label expansions, or clinical trial protocol adjustments if similar cases emerge, potentially affecting treatment protocols and reimbursement decisions for the BV franchise. Investors should monitor whether this generates post-marketing surveillance signals or regulatory guidance, as unexpected serious adverse events can impact prescriber adoption and expand litigation risk.

May 1, 2026

PubMed

Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.

# Investment Summary: Disitamab Vedotin in Urothelial Carcinoma Disitamab vedotin, a HER2-targeted antibody-drug conjugate (ADC), demonstrates clinical efficacy in HER2-negative and HER2-low urothelial carcinoma based on systematic review evidence, potentially expanding addressable market beyond HER2-positive tumors where ADCs currently dominate. This finding is relevant to Seagen's ADC pipeline strategy, as it validates the therapeutic approach in a solid tumor indication with limited treatment options, though the data suggests this may benefit competing manufacturers rather than Seagen directly unless the company has relevant programs in development. The clinical validation could reshape treatment paradigms in urothelial cancer but investors should monitor whether Seagen has corresponding development programs or partnership opportunities to participate in this emerging indication.

May 1, 2026

PubMed

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

# Seagen Investment Summary This phase 2 trial evaluates brentuximab vedotin (Adcetris, Seagen's anti-CD30 antibody-drug conjugate) in combination with checkpoint inhibitors (ipilimumab/nivolumab) for relapsed Hodgkin lymphoma, a key indication where Seagen has established market presence. Results demonstrating efficacy or safety advantages of this triple combination could expand Adcetris usage in heavily pretreated patients and support label expansion, though the trial may also inform optimal sequencing strategies that could affect treatment paradigms. For investors, outcomes will clarify whether Seagen's core asset maintains competitive positioning against emerging therapies and whether combination regimens can drive incremental revenue growth in this indication.

Apr 30, 2026

PubMed

Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.

# Seagen Investment Summary **Clinical/Commercial Implication:** This research demonstrates that blocking glycosphingolipid synthesis enhances CD30-targeted antibody efficacy by reducing N-glycan masking on the CD30 antigen, potentially improving response rates for Seagen's CD30-directed therapies (brentuximab vedotin and newer candidates). The finding suggests a combinatorial approach—pairing glycosphingolipid inhibitors with anti-CD30 antibodies—could overcome a mechanistic resistance pathway in Hodgkin lymphoma and CD30+ cutaneous T-cell lymphomas. **Investor Relevance:** If validated in preclinical models and clinical trials, this mechanism could expand market addressability by sensitizing currently resistant patients, supporting label expansions and combination therapy strategies. However, investors should monitor whether the glycosphingolipid inhibitor component introduces acceptable safety/tolerability

Apr 27, 2026

Seagen Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research